Get the Stockscreener App
3.14
1.88%
-0.06
After Hours:
3.14
Protara Therapeutics Inc stock is traded at $3.14, with a volume of 157.70K.
It is down -1.88% in the last 24 hours and up +2.28% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.20
Open:
$3.17
24h Volume:
157.70K
Relative Volume:
0.58
Market Cap:
$121.15M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.1135
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-0.32%
1M Performance:
+2.28%
6M Performance:
-22.85%
1Y Performance:
+81.50%
1-Day Range:
$3.12
$3.2386
1-Week Range:
$3.05
$3.2423
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.14 | 119.99M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Tools to monitor Protara Therapeutics Inc. recovery probabilityQuarterly Profit Review & Technical Pattern Based Signals - Newser
How to build a dashboard for Protara Therapeutics Inc. stockJuly 2025 Weekly Recap & Weekly High Potential Alerts - Newser
What institutional flow reveals about Protara Therapeutics Inc.2025 Earnings Impact & Technical Pattern Recognition Alerts - Newser
Candlestick signals on Protara Therapeutics Inc. stock todayEarnings Trend Report & Free Low Drawdown Momentum Trade Ideas - Newser
Using data models to predict Protara Therapeutics Inc. stock movementMarket Trend Summary & Fast Gain Swing Alerts - Newser
Visual trend scoring systems applied to Protara Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - Newser
Sector ETF performance correlation with Protara Therapeutics Inc.Fed Meeting & High Conviction Trade Alerts - Newser
Will Protara Therapeutics Inc. rebound enough to break evenLong Setup & Weekly Market Pulse Alerts - Newser
Using economic indicators to assess Protara Therapeutics Inc. potentialMarket Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Market reaction to Protara Therapeutics Inc.’s recent newsJuly 2025 Trends & Precise Trade Entry Recommendations - Newser
Is Protara Therapeutics Inc. reversing from oversold territoryEarnings Recap Summary & High Conviction Buy Zone Alerts - Newser
Using Python tools to backtest Protara Therapeutics Inc. strategiesIndex Update & AI Enhanced Trading Alerts - Newser
Can momentum traders help lift Protara Therapeutics Inc.2025 Price Momentum & Breakout Confirmation Alerts - Newser
Protara Therapeutics Inc. stock chart pattern explainedQuarterly Portfolio Review & Daily Momentum Trading Reports - Newser
What’s the recovery path for long term holders of Protara Therapeutics Inc.Weekly Trend Summary & Low Risk Entry Point Guides - Newser
Using data tools to time your Protara Therapeutics Inc. exitWeekly Investment Recap & Weekly High Conviction Ideas - Newser
How to use a screener to detect Protara Therapeutics Inc. breakoutsJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Breakouts Watch: What’s Protara Therapeutics Inc.’s historical return2025 Historical Comparison & Weekly High Return Stock Forecasts - Lancaster City Council
Does Protara Therapeutics Inc. fit your quant trading modelTrade Risk Summary & Weekly High Potential Alerts - Newser
Combining machine learning predictions for Protara Therapeutics Inc.Gap Down & Detailed Earnings Play Alerts - Newser
Can volume confirm reversal in Protara Therapeutics Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - Newser
Protara Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Institutional & Free Real-Time Volume Trigger Notifications - beatles.ru
What data driven models say about Protara Therapeutics Inc.’s futureQuarterly Market Review & Community Consensus Trade Signals - Newser
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):